Pay in 4 interest-free payments of $6.57 Learn more
Ships within 48 hours · Estimated delivery Nov 1 - Nov 6
Here are honest situations where another app fits the job better, plus where MeAgain wins on GLP-1 specifically
It's not something to replace with a supplement patch
However, direct cardiovascular outcome evidence specifically demonstrating superiority over semaglutide is not yet established
Key Takeaways Compound: Retatrutide (6.0-day half-life, GLP-1/GIP/glucagon triple agonist) Protocol length: 12 weeks covering 3 dosing phases Steady state: Reached in approximately 4.3 weeks at each dose level Transition period: Expect 4-5 weeks for levels to stabilize after a dose change Investigational Drug: Retatrutide is not FDA-approved and is currently in Phase 3 clinical trials
Hair thinning was reported by 3% of users, typically temporary and related to rapid weight loss rather than the compound
US$ 25.71
US$ 23.37
US$ 23.40
US$ 24.72
US$ 22.07
US$ 28.58
US$ 21.63
US$ 29.79
US$ 23.65
